Comparison of PK and Tolerability of MSB11022 Administered by AI or PFS

Conditions:   Rheumatoid Arthritis;   Polyarticular Juvenile Idiopathic Arthritis;   Psoriatic Arthritis;   Ankylosing Spondylitis;   Crohn Disease;   Ulcerative Colitis;   Plaque Psoriasis;   Pediatric Plaque Psoriasis;   Pediatric Crohns Disease;   Hidradenitis Suppurativa;   Non-inf ectious Uveitis Intervention:   Drug: 40 mg MSB11022 Sponsors:   Fresenius Kabi SwissBioSim GmbH;   PRA Health Sciences Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials